UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)
November 27, 2018

Twist Bioscience Corporation
(Exact name of registrant as specified in its charter)

Delaware	**001-38720**	**46-205888**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(I. R. S. Employer Identification No.)**

455 Mission Bay Boulevard South
Suite 545
San Francisco, CA 94158
(Address of principal executive offices, including ZIP code)

(800) 719-0671
(Registrant's telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 7.01 Regulation FD Disclosure.

Twist Bioscience Corporation (the "***Company***") is furnishing this Current Report on Form 8-K in connection with the disclosure of information, in the form of a PowerPoint presentation (the "***Presentation***"), to be used by the Company at various meetings with certain investors. This information may be amended or updated at any time and from time to time through another Current Report on Form 8-K, a later company filing or other means. A copy of the Presentation is furnished herewith as Exhibit 99.1 and is incorporated into this Item 7.01 by reference.

The information contained in the Presentation should be considered in the context of the Company's filings with the Securities and Exchange Commission and other public announcements the Company may make by press release or otherwise from time to time. The Presentation speaks as of the date of this Current Report on Form 8-K. By furnishing this Current Report on Form 8-K and furnishing the Presentation, the Company makes no admission as to the materiality of any information in this Current Report on Form 8-K, including without limitation the Presentation. The Company does not have, and expressly disclaims, any obligation to release publicly any updates or any changes in our expectations or any change in events, conditions, or circumstances on which any forward-looking statement in the Presentation is based.

The information furnished in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Presentation slide deck dated November 2018.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 27, 2018

Twist Bioscience Corporation

/s/ Mark Daniels

Mark Daniels
Senior Vice President, Chief Legal Officer,
Chief Ethics and Compliance Officer, and Secretary

Exhibit 99.1

Powering the Synthetic Biology Revolution

November 2018

@TwistBioscience #WeMakeDNA

Safe Harbor Statement

This presentation contains forward-looking statements. In particular, statements regarding future economic performance, finances, and expectations and objectives of management constitute forward-looking statements. Forward-looking statements can be identified by the fact that they do not relate strictly to historical facts and generally contain words such as "believes," "expects," "may," "will," "should," "seeks," "approximately," "intends," "plans," "estimates," "anticipates," and other expressions that are predictions of or indicate future events and trends and that do not relate to historical matters. Although the forward-looking statements contained in this presentation are based upon information available at the time the statements are made and reflect management's good faith beliefs, forward-looking statements inherently involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements to differ materially from anticipated future results. Important factors that could cause actual results to differ materially from expectations include, among others: our estimates of the size of our market opportunity; our expectations regarding our ability to increase gene production, reduce turnaround times and drive cost reductions for our customers; and our ability to enter new markets. You should not place undue reliance on these forward-looking statements, which speak only as of the date hereof. We do not undertake to update or revise any forward-looking statements after they are made, whether as a result of new information, future events, or otherwise, except as required by applicable law.

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. Neither we nor any other person makes any representation as to the accuracy or completeness of such data or undertakes any obligation to update such data after the date of this presentation. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

By attending or receiving this presentation you acknowledge that you will be solely responsible for your own assessment of the market and our market position and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of our business.

Experienced Management Team

	**Emily LeProust, PhD** President, CEO, Co-founder	Agilent Technologies	Director, Applications and Chemistry R&D—Genomics
	**Bill Banyai, PhD** COO, Co-founder	Complete genomics	VP Hardware Engineering
	**Bill Peck, PhD** CTO, Co-founder	Complete genomics	Director Fluidic Systems
	**Jim Thorburn** CFO	Televerde	Chief Sales Officer and Co-Head of International
	**Aaron Sato** CSO, Twist Pharma	LakePharma The Biologics Company	Chief Scientific Officer
	**Ray Tabibiazar** SVP Corporate Development	aravive BIOLOGICS	Founder and Executive Chairman
	**Patrick Finn, PhD** VP Sales and Marketing	enzymatics	VP Sales
	**Patrick Weiss** VP Operations	operon molecules for life	President and CEO
	**Paula Green** VP Human Resources	QIAGEN	VP Human Resources
	**Mark Daniels** GC, Chief Ethics and Compliance Officer	BROADCOM	VP Law and Deputy Chief Corporate Compliance Officer

Fueling the Industrialization of Biology

Writing Synthetic DNA on Silicon Platform

KEY ADVANTAGES OF WRITING DNA ON SILICON

MINIATURIZATION
10^{3-6} less volume of required reagents

THROUGHPUT
20M oligos/month

LOW COST
Driving adoption and new applications

VERSATILE PLATFORM
Broad applications

Our Versatile DNA Synthesis Platform Has Broad Applications

Twist's versatile DNA synthesis platform has broad application across many enabling synthetic biology products, and we are just beginning…

GENE SYNTHESIS
Product Available

DNA/ANTIBODY LIBRARIES
Product Available

CRISPR
Product Available

NGS BIODETECTION
Launched

DRUG DISCOVERY & DEVELOPMENT
Developing

DNA DATA STORAGE
Developing

DNA COMPUTING
Potential

Our Strategy

SYNTHETIC BIOLOGY: GENE SYNTHESIS → GENOMICS: TARGETED NGS → OPEN NEW MARKETS

Near-term strategic priorities | *Long-term initiatives*

- **Lead the Buyer market**
- **Convert Makers into Buyers**



*Source: Markets and Market Molecular Biology (2014)
BCC Research (2017)

Twist's advantages in…

Exome

- Performance
- Customization
- Full kit

Custom

- Turnaround time
- Affordable pilot and scaling
- NGS QC on all probes

- **Augment our product offering to meet the growing needs of our existing and potential new customers**
- **Expand into adjacent addressable markets**
- **Leverage our platform and industry partnerships to create new market opportunities for our products**


DRUG DISCOVERY


DATA STORAGE

Twist Bioscience Pipeline

MARKET OPPORTUNITIES	EXPLORATION	PROOF OF CONCEPT	BETA	COMMERCIAL	NEXT STEPS
Synthetic Biology: Synthetic Genes, DNA Libraries and Oligo Pools[1]					• Continue to drive growth • Expand market adoption
Genomics: Targeted NGS[2]					• Drive adoption of our NGS products • Launch NGS e-commerce platform
Biological Drug Discovery and Development[3]					• Validate GPCR library and Ab optimization solution • Establish partnerships
Digital Data Storage in DNA					• Continue to develop partnerships to explore digital data storage in DNA

[1] Products addressing this market include clonal, non-clonal genes (gene fragments), oligo pools and DNA libraries
[2] Products addressing this market include NGS exome capture and NGS custom capture
[3] Products addressing this market include custom DNA libraries, our proprietary GPCR-targeting antibody library and our antibody optimization solution

Twist's Platform Technology Addresses Multiple Large Market Opportunities

$1.3B

SYNTHETIC BIOLOGY

- Competitive Turnaround Time
- Lower Cost
- High Throughput
- High Quality

$0.5B

GENOMICS: NGS ENRICHMENT

- Fast Customization
- Performance
- Full Kit
- High Quality

SHORT TERM GOAL
Grow Revenue

Source: BCC Report (2017), Markets and Markets (2014) DeciBio (2015)

LARGE MARKET OPPORTUNITIES



LARGE MARKET

DRUG DISCOVERY/ DEVELOPMENT

- High Quality Diversity Hits / Leads
- Shorter Time and Cost from Target to IND

MID TERM GOAL
Develop novel therapeutics

$35B+

DATA STORAGE

- Permanence
- Density
- Ease of Copying
- Universal Format

LONG TERM GOAL
Enter technology market

Source: LDC Market Analysis, LTO Program Technology Provider Companies

Synthetic Biology is a Rapidly Growing $4B Opportunity

NEEDS	NEW APPLICATIONS FOR SYNTHETIC DNA
 **Healthcare** • Better drug development tools to lessen time and lower costs • More effective diagnostic tools for DNA extraction to lower costs (i.e. NGS)	• **Antibodies / TCR** • **Vaccines** • **Immuno and Cancer Therapies** • **Small Molecule Drug Manufacture**
 **Industrial** • Increased population growth impacting the sustainability of finite resources • Industrial production to address the needs of civilization	• **Specialty Chemicals** • **Advanced Property Materials**
 **Agriculture** • Global population growing with decrease in per capita arable land • Food security and increased nutrition	• **Self-fertilizing crops** • **Oil-Free Fertilizers** • **Drought Solutions** • **New Disease Protection**

We need a new type of DNA supplier to meet demand

Source: BCC Research

Gene Synthesis Market: Buyers and Makers

$1.3B / Year

Large Scale, Commercial Users

Value: Speed, Throughput and Quality

“ **Can’t get what I need** ”



Small Scale, Academic Users

Price-Sensitive

“ **I Hate Cloning** ”

Source: BCC Report (2017), Markets and Markets Molecular Biology (2014)

Rewriting DNA with the Power of Silicon



96 WELL PLATE
makes 1 gene



TWIST SILICON PLATFORM
can make 9,600 genes

Developing Game-Changing Throughput and Cost through Quality and Speed at Scale

Key Advantages

TWIST VALUE PROPOSITION

HIGH QUALITY

UNIQUE CUSTOMER EXPERIENCE

LOWER COST

UNPRECEDENTED THROUGHPUT / SCALE

CONSISTENT RELABILITY

COMPETITIVE TURNAROUND TIME

COMPREHENSIVE PRODUCT OFFERING

Our Disruptive Technology is Enabling New Markets and Applications

Cost per base pair vs NGS market size



Source: Equity research, company filings
Note: NGS market data taken from U.S. DNA Sequencing Technology Markets - 2006 from Cowen and Next generation Sequencing market size, growth and trends (2011–2019) report from DeciBio

Synthesis cost per gene vs Synthetic Biology market



Source: Rob Carlson, February 2014, www.synthesis.cc

Global value of synthetic biology market



Source: BCC Research *Expected growth

A Market Leader in Gene Synthesis

Over 700 customers served in FY 2018[1]

INCLUDING:

- Seven of the top 20 pharma companies by revenue
- Ginkgo Bioworks - Contract for up to 1.3B base pairs over four years
- Three of the largest agricultural biotechnology companies that use synthetic biology
- >100 academic research institutions worldwide
- Microsoft - For use of DNA as a digital data storage medium

GINKGO BIOWORKS™ THE ORGANISM COMPANY

Microsoft

[1] Includes preliminary estimated data for the three months ended September 30, 2018

GENES SHIPPED

>240,000 genes shipped in FY 2018[1]

MONTHLY AVERAGE IN

2016 Jul-Sept	**2,544 genes shipped**
2017 Jul-Sept	**12,675 genes shipped**
2018 Jul-Sept	**23,611 genes shipped**

TWIST BIOSCIENCE TO PROVIDE

1.3 Billion* Base Pairs of DNA

to Ginkgo Bioworks to Support Expansion into New Industries

Rapidly expanding product portfolio

Supply includes genes up to 5kb

Power of Scale

Takes advantage of Twist's gene production capacity: 10,000 genes per month and still increasing

* Up to 1.3 Billion

A Unique Way to Order your DNA Online ...



e-Commerce is Complete as of May 2018



Disease Diagnostics

Targeted NGS is enabling reading of patient's and/or pathogen's DNA to inform precision or personalized medical treatment

- Reduced sequencing cost per sample
- Faster time to results
- Increased sensitivity / complete coverage of difficult regions

Targeted NGS value chain

Library Prep

- Enzyme, Buffer, Primers, Barcodes
- Kappa (acquired by Roche) has mind share

Capture

- Oligos (10s to 100,000s, pooled, high quantities)
  - **Catalog: All Exome (~20,000 known human genes)**
  - **Custom: panels of 1 to 1,000s of genes, customer specific**
- Buffer, beads, enzyme

$0.5B SAM

Sequencing

- DNA sequencing
- Illumina dominant
- Ion Torrent, PacBio, ONT niche players

Analysis

- Primary, secondary and tertiary analysis
- Standardized (GATK)

Clinical Report

- Optional
- Biology intensive

Applications

- Research
- Translational
- Molecular Dx
- Microbiology
- Applied Markets

Targeted NGS – Strong Value Proposition

PERFORMANCE / COST

High Uniformity
Low Sequencing Costs

CUSTOMIZATION

2-3 Weeks Design to Production
On Custom and Exome Panels

FULL KIT

All Consumables From One Provider

Strong Orders Growth



[1] Preliminary estimated data for the three months ended September 30, 2018. Our consolidated financial statements for the three months ended Sep 30, 2018 are not yet available. Accordingly, the information presented for this period reflects our preliminary estimates subject to the completion of our financial closing procedures and any adjustments that may result from the completion of the quarterly review of our consolidated financial statements. As a result, these preliminary estimates may differ from the actual results that will be reflected in our consolidated financial statements for the quarter when they are completed and publicly disclosed. These preliminary estimates may change and those changes may be material

Customer Growth



[1] Customer count includes preliminary estimated data for the three months ended September 30, 2018

Quarterly Revenue Ramp



[1] Estimates based on the low-point of the estimated range based on preliminary estimated data for the three months ended September 30, 2018. Our consolidated financial statements for the three months ended Sep 30, 2018 are not yet available. Accordingly, the information presented for this period reflects our preliminary estimates subject to the completion of our financial closing procedures and any adjustments that may result from the completion of the quarterly review of our consolidated financial statements. As a result, these preliminary estimates may differ from the actual results that will be reflected in our consolidated financial statements for the quarter when they are completed and publicly disclosed. These preliminary estimates may change and those changes may be material

Twist's Platform Extends to Other Growth Verticals

LARGE MARKET OPPORTUNITIES



$1.3B

SYNTHETIC BIOLOGY

- Competitive Turnaround Time
- Lower Cost
- High Throughput
- High Quality

$0.5B

GENOMICS: NGS ENRICHMENT

- Fast Customization
- Performance
- Full Kit
- High Quality

SHORT TERM GOAL
Grow Revenue

LARGE MARKET

DRUG DISCOVERY/ DEVELOPMENT

- High Quality Diversity Hits / Leads
- Shorter Time and Cost from Target to IND

MID TERM GOAL
Develop novel therapeutics

$35B+

DATA STORAGE

- Permanence
- Density
- Ease of Copying
- Universal Format

LONG TERM GOAL
Enter technology market

Source: BCC Report (2017), Markets and Markets (2014) DeciBio (2015)

Source: LDC Market Analysis, LTO Program Technology Provider Companies

Novel Protein Libraries for Drug Discovery

To Enable Efficiency in Drug Discovery

From **Needle** in a Haystack

- Random diversity
- Biased representation
- >99% inefficiency
- Lengthy optimization cycle
- Expensive process

To **Stack of Needles**

- Explicit
- Even representation
- Human repertoire based
- Fast
- Affordable

Precise Introduction of Variants, Diversity that **Enables Screening Efficiency**



Gene Synthesis

Single Site

Multi-Site

Stretch

Multi-Domain

Expanding Drug Discovery Capabilities

Enables Tackling Bio-Betters and Hard-to-Drug Targets



Bio-Betters

High Diversity, High Quality Molecules

- Affinity (pM)
- Half-life
- Expression
- Immunogenicity
- Solubility
- Druggability

Leveraging Technology to Develop Therapeutics for **Hard-to-Drug** Targets

Twist's Platform Extends to Other Growth Verticals

LARGE MARKET OPPORTUNITIES



$1.3B

SYNTHETIC BIOLOGY

- Competitive Turnaround Time
- Lower Cost
- High Throughput
- High Quality

$0.5B

GENOMICS: NGS ENRICHMENT

- Fast Customization
- Performance
- Full Kit
- High Quality

SHORT TERM GOAL
Grow Revenue

Source: BCC Report (2017), Markets and Markets (2014) DeciBio (2015)

LARGE MARKET

DRUG DISCOVERY/ DEVELOPMENT

- High Quality Diversity Hits / Leads
- Shorter Time and Cost from Target to IND

MID TERM GOAL
Develop novel therapeutics

$35B+

DATA STORAGE

- Permanence
- Density
- Ease of Copying
- Universal Format

LONG TERM GOAL
Enter technology market

Source: LDC Market Analysis, LTO Program Technology Provider Companies

DNA: Nature's Choice for Data Storage

MAN-MADE, NOT PERMANENT

STABLE FOR 1000s of YEARS

20,000 Years ago

Sequencing the nuclear genome of the extinct woolly mammoth

Webb Miller[1], Daniela I. Drautz[1], Aakrosh Ratan[1], Barbara Pusey[1], Ji Qi[1], Arthur M. Lesk[1], Lynn P. Tomsho[1], Michael D. Packard[1], Fangqing Zhao[1], Andrei Sher[2]‡, Alexei Tikhonov[3], Brian Raney[4], Nick Patterson[5], Kerstin Lindblad-Toh[5], Eric S. Lander[5], James R. Knight[6], Gerard P. Irzyk[6], Karin M. Fredrikson[7], Timothy T. Harkins[7], Sharon Sheridan[7], Tom Pringle[8] & Stephan C. Schuster[1]

40,000 Years ago

A Draft Sequence of the Neandertal Genome



Richard E. Green,[1]*†‡ Johannes Krause,[1]†§ Adrian W. Briggs,[1]†§ Tomislav Maricic,[1]†§ Udo Stenzel,[1]†§ Martin Kircher,[1]†§ Nick Patterson,[2]†§ Heng Li,[2]† Weiwei Zhai,[1]†‖ Markus Hsi-Yang Fritz,[4]† Nancy F. Hansen,[3]† Eric Y. Durand,[3]† Anna-Sapfo Malaspinas,[3]† Jeffrey D. Jensen,[5]† Tomas Marques-Bonet,[6,13]† Can Alkan,[7]† Kay Prüfer,[1]† Matthias Meyer,[1]† Hernán A. Burbano,[1]† Jeffrey M. Good,[1,8]† Rigo Schultz,[1] Ayinuer Aximu-Petri,[1] Anne Butthof,[1] Barbara Höber,[1] Barbara Höffner,[1] Madlen Siegemund,[1] Antje Weihmann,[1] Chad Nusbaum,[2] Eric S. Lander,[2] Carsten Russ,[2] Nathaniel Novod,[2] Jason Affourtit,[9] Michael Egholm,[9] Christine Verna,[23] Pavao Rudan,[10] Dejana Brajkovic,[11] Željko Kucan,[10] Ivan Gušic,[10] Vladimir B. Doronichev,[12] Liubov V. Golovanova,[12] Carles Lalueza-Fox,[13] Marco de la Rasilla,[14] Javier Fortea,[14]¶ Antonio Rosas,[15] Ralf W. Schmitz,[16,17] Philip L. F. Johnson,[18]† Evan E. Eichler,[7]† Daniel Falush,[19]† Ewan Birney,[4]† James C. Mullikin,[3]† Montgomery Slatkin,[3]† Rasmus Nielsen,[3]† Janet Kelso,[1]† Michael Lachmann,[1]† David Reich,[2,20]*† Svante Pääbo[1]*†

560,000 - 780,000 Years ago

Recalibrating *Equus* evolution using the genome sequence of an early Middle Pleistocene horse

Ludovic Orlando[1]*, Aurélien Ginolhac[1]*, Guojie Zhang[2]*, Duar
Enrico Cappellini[3], Bent Petersen[4], Ida Moltke[4,5], Philip L. F. J
Thorfinn Korneliussen[3], Anna-Sapfo Malaspinas[3], Josef Vogt[6],
Andrei Dolocan[13], Jesper Stenderup[1], Amhed M. V. Velazquez
Grant D. Zazula[14], Andaine Seguin-Orlando[1,15], Cecilie Morter
Jacobo Wetzstock[16], Kristian Gregersen[1,17], Knut H. Røed[18], V
Douglas F. Antczak[19], Mads F. Bertelsen[20], Soren Brunak[21,22],
John Mundy[20], Anders Krogh[1,4], M. Thomas P. Gilbert[1], Kurt
Jesper V. Olsen[16], Michael Hofreiter[23], Rasmus Nielsen[24], Bett



Data Storage in DNA

1 Coding

00 → A
01 → G
10 → C
11 → T

2 Synthesis

3 Storage

4 Retrieval

5 Sequencing



6 Decoding

A → 00
G → 01
C → 10
T → 11

Permanence ● Density ● Random Access ● Universal format

DNA Data Storage Trends and Projections



We believe new DNA technologies and cost efficiencies could surpass mature IT hardware solutions in 3–5 years

* DNA bases per byte for hard drive and tape shown at typical published encoding ranges from about 5:1 to 6.25:1

** All dotted lines represent extrapolations and assumes continued trajectory of historical trends, and that there will be continued decrease in price as technology improves.

*** Raw oligo pool cost extrapolation based on DARPA and another anticipated government-sponsored grant project objectives, both at specified time points

(1) www.genome. Gov (2) Bob Fontana, IBM Systems, Storage Media Overview, May 4,2016 (3) Bioeconomy Capital, Rob Carlson, January 20, 2018, www.synthesis.cc

Strong Momentum and Milestones Achieved



Quarterly Revenue Ramp

QUARTERLY REVENUE RAMP ($M)



Quarter ended	Dec'16	Mar'17	Jun'17	Sep'17	Dec'17	Mar'18	Jun'18	Sep'18
Order value ($M)	$2.7	$4.2	$4.4	$6.2	$7.4	$8.5	$10.7	$12.8[2]
# of customers	69	104	168	192	260	314	379	498[2]
Gross profit ($M)	($3.3)	($3.6)	($3.0)	($3.4)	($3.2)	($1.9)	($1.0)	($1.0)[1,2]
Loss from operations ($M)	($13.4)	($14.3)	($14.2)	($16.6)	($16.8)	($16.6)	($17.5)	($20.9)[1,2]

Cash, cash equivalents and short-term investments of $80.8M as of September 30, 2018[2]
Long-term debt of $9.7M as of September 30, 2018[2]

F4Q'18 Flash Financial Results[2]

Revenue
$8.0M - $8.3M
Orders
$12.8M
Customers
498 total customers
Gross Profit
($1.0M) – ($0.9M)
Loss from Operations
($20.9M) – ($19.5M)

[1] Estimates based on the low-point of the estimated range based on preliminary estimated data for the three months ended September 30, 2018; [2]Our consolidated financial statements for the three months ended Sep 30, 2018 are not yet available. Accordingly, the information presented for this period reflects our preliminary estimates subject to the completion of our financial closing procedures and any adjustments that may result from the completion of the quarterly review of our consolidated financial statements. As a result, these preliminary estimates may differ from the actual results that will be reflected in our consolidated financial statements for the quarter when they are completed and publicly disclosed. These preliminary estimates may change and those changes may be material

Strong Financial Profile

FULL-YEAR REVENUE ($M)



	Full-year 2016	Full-year 2017	Full-year 2018[1,2]
Order value ($M)	$1.2	$17.6	$39.4[1,2]
% growth YoY	--	*NM*	*124%*
# of customers	97	286	717[2]
Gross profit ($M)	($7.2)	($13.3)	($7.0)[1,2]
Loss from operations ($M)	($43.7)	($58.5)	($71.7)[1,2]
Net cash used in operating activities ($M)	($38.6)	($51.3)	--[3]

9-MONTHS REVENUE AS OF JUNE 30 ($M)

	9-months 2017	9-months 2018
Order value ($M)	$11.4	$26.6
% growth YoY	--	*134%*
# of customers	208	539
Gross profit ($M)	($9.9)	($6.1)
Loss from operations ($M)	($41.9)	($50.9)
Net cash used in operating activities ($M)	($39.8)	($49.5)

Note: all values over 200% denoted as NM; [1] Estimates based on the low-point of the flash range; [2] Our consolidated financial statements for the three months ended Sep 30, 2018 are not yet available. Accordingly, the information presented for this period reflects our preliminary estimates subject to the completion of our financial closing procedures and any adjustments that may result from the completion of the quarterly review of our consolidated financial statements. As a result, these preliminary estimates may differ from the actual results that will be reflected in our consolidated financial statements for the quarter when they are completed and publicly disclosed. These preliminary estimates may change and those changes may be material; [3] Not provided as financial statements for the period are not yet available

Significant opportunities to drive further growth



Why Twist?

Breakthrough Technology
1st DNA Writing on Silicon Platform

Broad Application
Multiple Product Categories and End Markets

High Revenue Growth
2016-2017 revenue growth of 375%

Large Growing Markets
Synthesis DNA, NGS TE, Drug Discovery and Data Storage

Unique Platform & Value Proposition
Focus on Speed, Affordability, and High Quality

Attractive Dynamics
No FDA Approvals or Reimbursements

Experienced Team
with Strong Backing

TWIST BIOSCIENCE

Financial summary

- **Completed initial public offering in October 2018**
- **Strong insider support as well as participation from new leading institutional life science investors**
- **Analyst research coverage: J.P. Morgan (Tycho Peterson), Cowen (Doug Schenkel), Catherine Schulte (Baird)**

Consolidated statements of operations and comprehensive loss ($000s)

	Fiscal year ended		Nine months ended	
	30-Sep-16	30-Sep-17	30-Jun-17	30-Jun-18
Revenues:				
Synthetic genes	$1,087	$8,122	$5,379	$11,903
Oligo pools	$862	$2,056	$1,512	$2,146
DNA libraries	$320	$517	$410	$1,208
NGS tools	—	$72	–	$1,763
Total revenues	**$2,269**	**$10,767**	**$7,301**	**$17,020**
Operating expenses:				
Cost of revenues	$9,421	$24,020	$17,191	$23,096
Research and development	$18,230	$19,169	$14,318	$14,282
Selling, general and administrative	$18,274	$26,060	$17,651	$30,497
Total operating expenses	**$45,925**	**$69,249**	**$49,160**	**$67,875**
Loss from operations	($43,656)	($58,482)	($41,859)	($50,855)
Total interest income and expenses	($505)	($493)	($432)	($337)
Other income (expense)	$73	($55)	$151	($76)
Loss before income taxes	**($44,088)**	**($59,030)**	**($42,140)**	**($51,268)**
Provision for income taxes	—	($280)	($161)	($166)
Net loss	**($44,088)**	**($59,310)**	**($42,301)**	**($51,434)**